vs
Side-by-side financial comparison of QuidelOrtho Corp (QDEL) and WillScot Holdings Corp (WSC). Click either name above to swap in a different company.
QuidelOrtho Corp is the larger business by last-quarter revenue ($699.9M vs $566.0M, roughly 1.2× WillScot Holdings Corp). WillScot Holdings Corp runs the higher net margin — -33.1% vs -104.7%, a 71.6% gap on every dollar of revenue. On growth, QuidelOrtho Corp posted the faster year-over-year revenue change (-3.7% vs -6.1%). WillScot Holdings Corp produced more free cash flow last quarter ($149.7M vs $-94.7M). Over the past eight quarters, WillScot Holdings Corp's revenue compounded faster (-1.8% CAGR vs -2.9%).
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
WillScot Holdings Corp is a leading provider of modular space solutions and portable storage services across North America. It serves a wide range of sectors including construction, commercial development, education, healthcare, government projects, and special events, offering flexible, scalable temporary and semi-permanent space solutions tailored to diverse client needs.
QDEL vs WSC — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $699.9M | $566.0M |
| Net Profit | $-733.0M | $-187.3M |
| Gross Margin | — | 50.4% |
| Operating Margin | -100.7% | -32.5% |
| Net Margin | -104.7% | -33.1% |
| Revenue YoY | -3.7% | -6.1% |
| Net Profit YoY | -3583.4% | -310.0% |
| EPS (diluted) | $-10.78 | $-1.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $566.0M | ||
| Q3 25 | $699.9M | $566.8M | ||
| Q2 25 | $613.9M | $589.1M | ||
| Q1 25 | $692.8M | $559.6M | ||
| Q4 24 | $707.8M | $602.5M | ||
| Q3 24 | $727.1M | $601.4M | ||
| Q2 24 | $637.0M | $604.6M | ||
| Q1 24 | $711.0M | $587.2M |
| Q4 25 | — | $-187.3M | ||
| Q3 25 | $-733.0M | $43.3M | ||
| Q2 25 | $-255.4M | $47.9M | ||
| Q1 25 | $-12.7M | $43.1M | ||
| Q4 24 | $-178.4M | $89.2M | ||
| Q3 24 | $-19.9M | $-70.5M | ||
| Q2 24 | $-147.7M | $-46.9M | ||
| Q1 24 | $-1.7B | $56.2M |
| Q4 25 | — | 50.4% | ||
| Q3 25 | — | 49.7% | ||
| Q2 25 | — | 50.3% | ||
| Q1 25 | — | 53.7% | ||
| Q4 24 | — | 55.8% | ||
| Q3 24 | — | 53.5% | ||
| Q2 24 | — | 54.1% | ||
| Q1 24 | — | 54.0% |
| Q4 25 | — | -32.5% | ||
| Q3 25 | -100.7% | 21.0% | ||
| Q2 25 | -29.4% | 21.5% | ||
| Q1 25 | 4.7% | 21.3% | ||
| Q4 24 | -14.2% | 28.9% | ||
| Q3 24 | 2.1% | -5.9% | ||
| Q2 24 | -18.4% | -0.9% | ||
| Q1 24 | -247.3% | 22.1% |
| Q4 25 | — | -33.1% | ||
| Q3 25 | -104.7% | 7.6% | ||
| Q2 25 | -41.6% | 8.1% | ||
| Q1 25 | -1.8% | 7.7% | ||
| Q4 24 | -25.2% | 14.8% | ||
| Q3 24 | -2.7% | -11.7% | ||
| Q2 24 | -23.2% | -7.7% | ||
| Q1 24 | -239.9% | 9.6% |
| Q4 25 | — | $-1.02 | ||
| Q3 25 | $-10.78 | $0.24 | ||
| Q2 25 | $-3.77 | $0.26 | ||
| Q1 25 | $-0.19 | $0.23 | ||
| Q4 24 | $-2.54 | $0.48 | ||
| Q3 24 | $-0.30 | $-0.37 | ||
| Q2 24 | $-2.20 | $-0.25 | ||
| Q1 24 | $-25.50 | $0.29 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $98.1M | $14.6M |
| Total DebtLower is stronger | $2.5B | $3.6B |
| Stockholders' EquityBook value | $2.0B | $856.3M |
| Total Assets | $5.7B | $5.8B |
| Debt / EquityLower = less leverage | 1.23× | 4.15× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $14.6M | ||
| Q3 25 | $98.1M | $14.8M | ||
| Q2 25 | $151.7M | $12.8M | ||
| Q1 25 | $127.1M | $10.7M | ||
| Q4 24 | $98.3M | $9.0M | ||
| Q3 24 | $143.7M | $11.0M | ||
| Q2 24 | $107.0M | $5.9M | ||
| Q1 24 | $78.5M | $13.1M |
| Q4 25 | — | $3.6B | ||
| Q3 25 | $2.5B | $3.6B | ||
| Q2 25 | $2.1B | $3.7B | ||
| Q1 25 | $2.1B | $3.6B | ||
| Q4 24 | $2.1B | $3.7B | ||
| Q3 24 | $2.2B | $3.6B | ||
| Q2 24 | $2.2B | $3.5B | ||
| Q1 24 | $2.2B | $3.5B |
| Q4 25 | — | $856.3M | ||
| Q3 25 | $2.0B | $1.1B | ||
| Q2 25 | $2.8B | $1.0B | ||
| Q1 25 | $3.0B | $1.0B | ||
| Q4 24 | $3.0B | $1.0B | ||
| Q3 24 | $3.2B | $1.1B | ||
| Q2 24 | $3.2B | $1.2B | ||
| Q1 24 | $3.3B | $1.3B |
| Q4 25 | — | $5.8B | ||
| Q3 25 | $5.7B | $6.1B | ||
| Q2 25 | $6.4B | $6.1B | ||
| Q1 25 | $6.5B | $6.0B | ||
| Q4 24 | $6.4B | $6.0B | ||
| Q3 24 | $6.8B | $6.0B | ||
| Q2 24 | $6.7B | $6.0B | ||
| Q1 24 | $6.7B | $6.2B |
| Q4 25 | — | 4.15× | ||
| Q3 25 | 1.23× | 3.39× | ||
| Q2 25 | 0.74× | 3.55× | ||
| Q1 25 | 0.70× | 3.56× | ||
| Q4 24 | 0.72× | 3.62× | ||
| Q3 24 | 0.68× | 3.42× | ||
| Q2 24 | 0.70× | 2.88× | ||
| Q1 24 | 0.68× | 2.63× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-45.5M | $158.9M |
| Free Cash FlowOCF − Capex | $-94.7M | $149.7M |
| FCF MarginFCF / Revenue | -13.5% | 26.5% |
| Capex IntensityCapex / Revenue | 7.0% | 1.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-153.1M | $737.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $158.9M | ||
| Q3 25 | $-45.5M | $191.2M | ||
| Q2 25 | $-46.8M | $205.3M | ||
| Q1 25 | $65.6M | $206.6M | ||
| Q4 24 | $63.7M | $178.9M | ||
| Q3 24 | $117.9M | $-1.6M | ||
| Q2 24 | $-97.9M | $175.6M | ||
| Q1 24 | $-700.0K | $208.7M |
| Q4 25 | — | $149.7M | ||
| Q3 25 | $-94.7M | $186.9M | ||
| Q2 25 | $-84.3M | $199.0M | ||
| Q1 25 | $9.4M | $202.0M | ||
| Q4 24 | $16.5M | $176.6M | ||
| Q3 24 | $71.4M | $-4.9M | ||
| Q2 24 | $-133.2M | $169.4M | ||
| Q1 24 | $-66.8M | $202.1M |
| Q4 25 | — | 26.5% | ||
| Q3 25 | -13.5% | 33.0% | ||
| Q2 25 | -13.7% | 33.8% | ||
| Q1 25 | 1.4% | 36.1% | ||
| Q4 24 | 2.3% | 29.3% | ||
| Q3 24 | 9.8% | -0.8% | ||
| Q2 24 | -20.9% | 28.0% | ||
| Q1 24 | -9.4% | 34.4% |
| Q4 25 | — | 1.6% | ||
| Q3 25 | 7.0% | 0.7% | ||
| Q2 25 | 6.1% | 1.1% | ||
| Q1 25 | 8.1% | 0.8% | ||
| Q4 24 | 6.7% | 0.4% | ||
| Q3 24 | 6.4% | 0.6% | ||
| Q2 24 | 5.5% | 1.0% | ||
| Q1 24 | 9.3% | 1.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | 4.41× | ||
| Q2 25 | — | 4.28× | ||
| Q1 25 | — | 4.80× | ||
| Q4 24 | — | 2.01× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 3.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
WSC
| Modular Space Leasing | $249.8M | 44% |
| Value Added Product And Services | $101.0M | 18% |
| Portable Storage Leasing | $83.0M | 15% |
| Delivery Revenue | $48.2M | 9% |
| Installation Revenue | $45.0M | 8% |
| Rental Units | $19.7M | 3% |
| New Units | $15.5M | 3% |
| Value Added Services | $10.3M | 2% |
| Other Leasing Related Products And Services | $3.8M | 1% |
